Diagnostic biomarkers of acute exacerbation of chronic obstructive pulmonary disease at elderly patients

Acute exacerbations of chronic obstructive pulmonary disease are caused by a variety of different etiologies. The aim of the current study was to determine the diagnostic biomarkers for verifying the diagnosis of acute exacerbations of chronic obstructive pulmonary disease and predicting the length of hospital stay at elderly patients. The f iles of 120 patients who had been hospitalized with the diagnose of acute exacerbation of chronic obstructive pulmonary disease between January 2017 to December 2018 in the Chest Disease Department of Gulhane Education and Training Hospital were examined retrospectively. The numbers and the percentage of male and female patients were 83 (% 69) and 37 (% 31) respectively. Increases in the prohormone brain natriuretic peptide values of elderly patients were found as statistically significant (p

PDF

___

Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415.

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.

Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347-65.

Quon BS, Gan WQ, Sin DD. Contemporary Management of Acute Exacerbations of COPD: A Systematic Review and Metaanalysis. Chest. 2008;133:756-66.

Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The reduce randomized clinical trial. JAMA. 2013;309:2223-31.

Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67:238-43.

Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:209-10.

Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38:2935.

Jones PW, Harding G, Berry P, Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648-54.

10. Lee SD, Huang MS, Kang J, et al. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Respir Med. 2014;108:600-8.

11. Jones PW, Adamek L, Nadeau G, et al. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013;42:647-54.

12. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.

13. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.

14. Calzetta L, Orlandi A, Page C, et al. Brain natriuretic peptide: Much more than a biomarker. Int J Cardiol. 2016;221:1031-8.

15. Doyama K, Fukumoto M, Takemura G, et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol. 1998;32:1832-8.

16. Hill NS, Klinger JR, Warburton RR, et al. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol. 1994;266:308-15.

17. Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest. 1996;110:1220-5.

18. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;63:261-8.

19. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66:764-768.

20. Hoiseth AD, Omland T, Karlsson BD, et al. Standardized evaluation of lung congestion during COPD exacerbation better identifies patients at risk of dying. Int J Chron Obstruct Pulmon Dis. 2013;8:621-9.

21. Hopstaken RM, Witbraad T, van Engelshoven JM, et al. Interobserver variation in the interpretation of chest radiographs for pneumonia in communityacquired lower respiratory tract infections. Clin Radiol. 2004;59:743-52.

22. SA Alavi, F Soati, K Forghanparast, et al. HsCRP in patients with acute exacerbation of chronic obstructive pulmonary disease. Iran Red Crescent Med J. 2011;13:713-8.

23. Breyer MK, Spruit MA, Celis AP, et al. CIRO Network. Highly elevated C-reactive protein levels in obese patients with COPD: A fat chance. Clin Nutr. 2009;28:642-7.

24. Kony S, Zureik M, Driss F, et al. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax. 2004;59:892-6.

25. Ghobadi H, Fouladi N, Beukaghazadeh K, et al. Association of high sensitive CRP level and COPD assessment test scores with clinically important predictive outcomes in stable COPD patients. Tanaffos. 2015;14:34-41.

26. Bridevaux PO, Gerbase MW, Schindler C, et al. Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2. Eur Respir J. 2009;34:332-29.

27. Pinto-Plata VM, Mollerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61:23-8.

28. Sahebjami H, Sathianpitayakul E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:886-90.

29. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008;133:1336-43.

30. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902-7.

31. Halvani A, Nadooshan HH, Shoraki FK, et al. Serum C-reactive protein level in COPD patients and normal population. Tanaffos. 2007;6:51-5.

32. El Mallawany H, Mahmoud MI, Morsi TS, et al. Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 2014;63:57-65.

33. Chen YR, Chen V, Hollander Z, et al. C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations, Plos one. 2017;12:0174063.

34. McCullough PA, Duc P, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-9.

35. Souza R, Bogossian HB, Humbert M, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005;25:509-13.

36. Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown). 2011;12:613-8.

37. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortalityrelated factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459-67.

38. Hoiseth AD, Omland T, Hagve TA, NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res.2012;13:97.

39. Adrish M, Nannaka VB, Cano EJ, et al. Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction. Int J Chron Obstruct Pulmon Dis. 2017:12;1183-9.